Immune Signature Analysis for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand the relationship between certain blood markers, such as circulating tumor DNA (ctDNA), and the progression of lung cancer after immunotherapy. It targets individuals with metastatic non-small cell lung cancer (mNSCLC) who have received immune checkpoint inhibitor treatments for nearly two years. Participants should have completed most of their treatment and still be eligible for maintenance chemotherapy. This research could help predict cancer progression and improve future treatments. As a Phase 2 trial, it measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to advancements in cancer care.
Will I have to stop taking my current medications?
The trial allows patients to continue maintenance chemotherapy, so you may not need to stop all your current medications. However, the protocol does not specify about other medications, so it's best to discuss with the trial team.
Why are researchers excited about this trial?
Researchers are excited about this trial because it focuses on using biomarkers and circulating tumor DNA (ctDNA) to better understand disease progression in lung cancer patients after immunotherapy. Unlike traditional treatments that primarily aim to shrink tumors, this approach seeks to identify specific genetic signatures that could predict how a patient's cancer might change or resist treatment. By analyzing blood and tissue samples, researchers hope to personalize future treatments and improve outcomes for patients with metastatic non-small cell lung carcinoma. This could lead to more precise and effective therapies, tailored to the unique genetic makeup of each patient's cancer.
Who Is on the Research Team?
Kathryn Mileham, MD
Principal Investigator
Atrium Health Levine Cancer
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive immune checkpoint inhibitor treatment for at least 20 of an anticipated 24 months
Follow-up
Participants are monitored for disease progression and biomarker analysis after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Biomarkers and ctDNA
- Blood and tissue samples
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Biomarkers and ctDNA data generated from patients with metastatic non-small cell lung carcinoma who have completed first line immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor platinum doublet combination therapy, and have, at immunotherapy discontinuation, completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor treatment.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Atrium Health Wake Forest Baptist
Collaborator
Atrium Health Levine Cancer Institute
Collaborator
Atrium Health Wake Forest Baptist
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.